A rose by any other name: TGA delivers decision on biosimilar identifiers

After a year of consultation, the TGA has rejected proposals for a unique naming system to differentiate biosimilar medicines from their biologic originators. This week, the TGA announced it would not adopt an ARA-backed option to add a unique suffix to each biosimilar, but would instead maintain the current naming convention that relies on non-proprietary ...